This co-expression of various exhaustion markers with increasing levels of PD-1 has been seen in other cancers including in NSCLC, where PD-1 high CD8+ TILs represent a distinct population enriched for effector functions, tumour reactivity and are associated with response to ICB [13]. The gene discussed is PDCD1; the disease is neoplasm.